# GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

> **NCT04796428** · PHASE4 · UNKNOWN · sponsor: **Center for Outcomes Research and Clinical Epidemiology, Italy** · enrollment: 1167 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin
- **DRUG:** Dapagliflozin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT04796428
- **Lead sponsor:** Center for Outcomes Research and Clinical Epidemiology, Italy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-30
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 1167 (ESTIMATED)
- **Last updated:** 2021-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796428, "GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04796428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*